Alzheimer’s Matters, the official blog of the ADDF, features insights, perspectives and commentary on current topics of interest in Alzheimer’s disease and related drug discovery.

Closing in on a Cure: Oryzon Genomics and ORY-2001

01/17/2017

Discover ORY-2001, a revolutionary epigenetic therapy for Alzheimer's disease being developed by Oryzon Genomics in Barcelona, Spain. 

Top Five Alzheimer’s Advances in 2016

01/10/2017

In 2016, we made 46 new grants totaling $16.3 million. This brought us to an important milestone—$100 million invested in drugs to prevent, treat, and ultimately cure Alzheimer’s. And we are closing in on a cure. Over the past year, we made great progress, as our top five advances demonstrate.

Closing in on a Cure: Dr. Frank Longo and C-31

12/15/2016

We have supported over 20% of all the treatments for Alzheimer’s currently in clinical trials. One of the most promising of these is C-31, developed by Frank Longo, MD, PhD.

Striding Toward $100 Million on Giving Tuesday

11/28/2016

Since 1998, the ADDF has invested $97 million in critical research and—with your #GivingTuesday donation—we will reach $100 million this year.

What Does the Failure of Solanezumab Mean?

11/25/2016

Eli Lilly announced that its Alzheimer's drug solanezumab failed in its last phase 3 clinical trial. Howard Fillit, MD, discusses what this means for the field and for patients, and where we go from here.

Looking Ahead on World Alzheimer’s Day

09/21/2016

On World Alzheimer’s Day, we celebrate the progress made and look toward the future. 

Advancing Epigenetics: A New Approach to Treating Alzheimer’s Disease

09/12/2016

Executive Director Howard Fillit, MD, discusses epigenetic treatments, one of the newest and most promising areas of our portfolio. 

My Marathon Journey with the ADDF

09/07/2016

Ernest Scheyder, a returning member of the ADDF’s TCS NYC Marathon team, shares why he is running for Alzheimer’s research and how you can help him and the rest of our dedicated runners.

ADDF-Funded PET Imaging Makes Clinical Trial Success Possible

09/02/2016

For the first time, a treatment has reduced amyloid beta plaques in the brains of patients with Alzheimer’s disease. 

The Enduring Legacy of NFL Star Tommy Mason

07/06/2016

Karen Mason reflects on her late husband, Tommy Mason, whom she describes as "larger than life," a trait that remained even as he endured the effects of Alzheimer’s.